Nigeria says it will continue to make use of hydroxychloroquine as clinical trial for the treatment of COVID-19 patients in spite of the directives by the World Health Organisation (WHO) halting such trials.
A critical regulatory agency, the National Agency for Food and Drug Administration and Control (NAFDAC) stated this on Tuesday by its Director-General, Prof. Mojisola Adeyeye, during an interview with Channels TV.
She alluded that she was not aware of the data WHO used in coming up with the suspension of the drug as treatment for COVID-19, adding that
Nigeria will still continue the clinical trial for now.
WHO had suspended the use of hydroxychloroquine for clinical trial for coronavirus, saying the drug has caused deaths to people using it to treat the virus.
“I do not know the data that they are looking at, whether it is from the Caucasian population or from the African population. I know that the clinical trial treatment is about to start or have started a few days ago in Lagos.
“When you do clinical trial treatment, there are many factors that can affect the clinical outcome. The way drug is handled even from children from the same mother may be different, not to talk of populations.
“So if the data they are looking at and the reason for suspending the trials is because it is from a Caucasian population, then it may be justified. I don’t think we have data from the African population yet because our genetic makeup is different.
“You can take for example drugs used for Hypertension. There are some drugs that would work for the African American or African population that will not work for the Caucasian population.
“When you are doing Science experiment or clinical trial, you wait for data. Once we start getting our own data in Africa, then we can go one way or the other,” Professor Adeyeye added.